𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chemoprevention strategies for prostate cancer: The role of 5α-reductase inhibitors

✍ Scribed by Glenn J. Gormley

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
445 KB
Volume
50
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Prostate cancer is a major health problem for the aging male population. Despite hormonal dependence, the inevitable emergence of androgen insensitive tumors, which have a dismal prognosis, highlights the need to develop prevention strategies such as chernoprevention. An acceptable agent must interfere with eitherthe processof carcinogenesis or tumor growth, and have minimal toxicity. In clinical studies, 5a-reductase inhibitors have been shown to suppress serum and intraprostatic levels of dihydrotestosterone, an important promoter of prostate cancer, leading to reduction in prostate size and suppression of glandular cell activity as measured by prostate specific antigen secretion. In addition, 5a-reductase inhibitors have demonstrated an excellent safety profile and tolerability in 12 month controlled clinical trials. No significant metabolic effects have been observed in gonadotropin secretion, spermatogenesis, serum lipids or glucose tolerance. The efficacy and safety of 5a-reductase inhibitors in studies to date, combined with the androgen dependence of tumor production, strongly supports investigating their use for chemoprevention of prostate cancer.

📜 SIMILAR VOLUMES

Castration-like effects on the human pro
Castration-like effects on the human prostate of a 5α-reductase inhibitor, finasteride
✍ Jack Geller; Lida Sionit 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB

Epidemiological studies strongly support the contention that surgical castration prior to age forty prevents both benign prostatic hypertrophy (BPH) and prostate cancer. 5 alpha-Reductase deficiency in humans, an experiment of nature, is an uncommon genetically transmitted disorder in which prostate

Effect of early treatment of prostate ca
Effect of early treatment of prostate cancer with the 5α-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats
✍ Zaccheo, Tiziana; Giudici, Donata; di Salle, Enrico 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 1 views

## Background: Turosteride, a selective 5alpha-reductase inhibitor, was reported to be effective in inhibiting the growth of established tumors in the dunning r3327 rat prostatic carcinoma model. we evaluated the preventive effect of turosteride when administered during the latency period in this p

Effect of turosteride, a 5α-reductase in
Effect of turosteride, a 5α-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma
✍ Zaccheo, T.; Giudici, D.; di Salle, E. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB 👁 1 views

BACKGROUND. Turosteride (FCE 26073) is a new, potent, and selective 5␣-reductase inhibitor. We have investigated its effect on tumor growth, organ weight, and serum hormone levels in rats bearing the androgen sensitive Dunning R3327 prostatic carcinoma. METHODS. Animals with tumor diameters of 0.5-1

Polymorphic markers in the 5α-reductase
Polymorphic markers in the 5α-reductase type II gene and the incidence of prostate cancer
✍ Najib Lamharzi; Melissa M. Johnson; Gary Goodman; Ruth Etzioni; Noel S. Weiss; D 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 73 KB

## Abstract In the prostate, the enzyme encoded by the __SRD5A2__ gene (5α‐reductase) converts testosterone to dihydrotestosterone, a potent androgen that has been hypothesized to play a role in the genesis of prostate cancer. Several polymorphisms have been identified in the __SRD5A2__ gene, inclu

Serenoa repens (Permixon®) inhibits the
Serenoa repens (Permixon®) inhibits the 5α-reductase activity of human prostate cancer cell lines without interfering with PSA expression
✍ Fouad K. Habib; Margaret Ross; Clement K.H. Ho; Valerie Lyons; Karen Chapman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 109 KB 👁 1 views

## Abstract The phytotherapeutic agent Serenoa repens is an effective dual inhibitor of 5α‐reductase isoenzyme activity in the prostate. Unlike other 5α‐reductase inhibitors, Serenoa repens induces its effects without interfering with the cellular capacity to secrete PSA. Here, we focussed on the p